Feature Channels: Pharmaceuticals

Filters close
Released: 8-Nov-2023 12:05 PM EST
Disturbances in sensory neurons may alter transient pain into chronic pain
University Medical Center Utrecht

Transient inflammatory pain causes long-lasting mitochondrial changes in sensory neurons, contributing to chronic pain.

Released: 8-Nov-2023 9:50 AM EST
Forward Therapeutics Announces $50 Million Series A Financing to Advance Next-Generation Small Molecule Immune Therapies
Forward Therapeutics

Forward Therapeutics, Inc., a biopharmaceutical company developing next-generation small molecule therapies for chronic immunological and inflammatory disorders, today announced a $50 million Series A financing.

   
Released: 8-Nov-2023 9:05 AM EST
First Precision Health Trial for Dup15q Syndrome Begins
Children's Hospital Los Angeles

Children’s Hospital Los Angeles has launched a new clinical trial to investigate a potential treatment for Dup15q syndrome, a rare genetic condition that causes developmental delays, autism spectrum disorder and epilepsy.

3-Nov-2023 8:00 AM EDT
A step to prevent opioid overdose deaths with light-activated naloxone treatment
American Chemical Society (ACS)

In a proof-of-concept in ACS’ Nano Letters, a team has designed injectable nanoparticles that released naloxone ― which rapidly reverses opioid overdose effects ― when triggered by blue light. In experiments with mice, this system was activated a month after injection.

Newswise: New Research in JNCCN Suggests a Simple and Inexpensive Option for Reducing a Major Chemotherapy Side-Effect
3-Nov-2023 10:05 AM EDT
New Research in JNCCN Suggests a Simple and Inexpensive Option for Reducing a Major Chemotherapy Side-Effect
National Comprehensive Cancer Network® (NCCN®)

New research in the November 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network suggests that breast cancer patients who have insufficient levels of vitamin D before starting paclitaxel treatment are more likely to experience peripheral neuropathy.

Released: 7-Nov-2023 11:05 AM EST
Contraceptive pills might impair fear-regulating regions in women’s brains
Frontiers

Scientists find the use of oral contraceptives may affect fear-related brain morphology, knowledge that could deepen understanding of fear-related mechanisms that primarily affect women

Newswise: BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™
Released: 7-Nov-2023 8:05 AM EST
BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™
BioReference Health, LLC

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that BioReference® Health, LLC, an OPKO Health, Inc. company and full-service laboratory that processes more than 12 million tests annually, will implement SOPHiA GENETICS' technology and add MSK-ACCESS® liquid biopsy to its test suite.

Released: 7-Nov-2023 7:45 AM EST
MD Anderson and Jazz Pharmaceuticals announce five-year collaboration to evaluate zanidatamab in HER2-expressing cancers
University of Texas MD Anderson Cancer Center

MD Anderson and Jazz Pharmaceuticals announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz’s investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers.

Newswise: Medicare Could Save an Additional $10 Billion Annually Across 10 Drugs by Using a Therapeutic Reference Pricing Approach in Upcoming Price Negotiations
Released: 7-Nov-2023 4:05 AM EST
Medicare Could Save an Additional $10 Billion Annually Across 10 Drugs by Using a Therapeutic Reference Pricing Approach in Upcoming Price Negotiations
ISPOR—The Professional Society for Health Economics and Outcomes Research

Value in Health announced the publication of a study showing that United States Medicare could save up to an additional $5-$10 billion dollars annually across 10 drugs if it negotiated prices using a therapeutic reference pricing approach rather than using the statutory ceiling price alone.

Released: 6-Nov-2023 6:05 PM EST
Rakuten Medical Presents AI-based Study in Two Posters on Immune Characteristics in Responders and Cellular Level Drug Quantification of Alluminox Treatment (Photoimmunotherapy) at SITC 2023
Rakuten Medical, Inc.

Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell-targeted therapies based on its proprietary Alluminox™ platform today announced the presentation of two posters of AI-based analyses at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held November 3-5, 2023, in San Diego, CA (SITC 2023).

Released: 6-Nov-2023 4:05 PM EST
First in human trial of new drug raises hopes for patients with relapsed blood cancer
Ohio State University Wexner Medical Center

A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), may offer a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia and Non-Hodgkin lymphoma whose disease has stopped responding to standard treatments.

Newswise: Researchers Use a Novel Approach to Design a COVID-19 Antiviral Drug
Released: 6-Nov-2023 3:05 PM EST
Researchers Use a Novel Approach to Design a COVID-19 Antiviral Drug
Department of Energy, Office of Science

Researchers combined the features of clinical drugs to treat hepatitis C and viruses similar to COVID-19. This allowed them to synthesize BBH-1, a promising inhibitor that targets the breakdown of the SARS-CoV-2 virus. The researchers characterized samples using X-ray and neutron diffraction techniques to provide atomic-level insights on the structure of the BBH-1 inhibitor and how it binds to the SARS-CoV-2 protein.

Released: 6-Nov-2023 10:05 AM EST
Incheon National University scientists develop new hydrogels for wound management
Incheon National University

By leveraging the power of oxygen, these gelatin patches can act as effective tissue adhesives that accelerate the healing of wounds

Released: 6-Nov-2023 7:00 AM EST
Pharma Industry Consortium to Present Data from large Ketamine-challenge Study at CNS Summit
ERP Biomarker Qualification Consortium

The ERP Biomarker Qualification Consortium announced today that they will be presenting data from a recently completed, pharma industry sponsored study that measured the electrophysiologic effects of ketamine on healthy brain function, at the CNS Summit 2023 in Boston.

   
Released: 3-Nov-2023 12:05 PM EDT
Neutralizing antibodies that target resistant bacteria
German Center for Infection Research (Deutsches Zentrum für Infektionsforschung - DZIF)

Antibiotic-resistant bacteria pose a major challenge to healthcare systems worldwide. Due to numerous resistance mechanisms, infections with the pathogen Pseudomonas aeruginosa are particularly feared. Researchers at the German Center for Infection Research (DZIF), the University Hospital Cologne, the Helmholtz Centre for Infection Research in Braunschweig and the University Medical Center Hamburg-Eppendorf have now discovered antibodies that could lead to a highly potent treatment option of acute and chronic infections with P. aeruginosa. The study was published in the prestigious scientific journal Cell.

Released: 3-Nov-2023 10:05 AM EDT
Human insulin less temperature-sensitive than previously thought
Cochrane

A new Cochrane review has found that insulin can be kept at room temperature for months without losing potency, offering hope to people living with diabetes in regions with limited access to healthcare or stable powered refrigeration

Released: 1-Nov-2023 2:05 PM EDT
Cancer drug could hold hope for treating inflammatory diseases including gout and heart diseases
University of Cambridge

Cancer drug could treat inflammatory diseases by calming down the inflammatory response

Released: 1-Nov-2023 1:05 PM EDT
Unveiling the hidden power for drug-target interaction prediction: a game-changing approach
Higher Education Press

FragDPI, a novel drug-protein interaction prediction method, outperforms baselines and identifies specific interaction parts, aiding drug discovery

Newswise: Cancer drug shows promise targeting genetic weakness in some tumors, comments Virginia Tech expert
31-Oct-2023 12:00 AM EDT
Cancer drug shows promise targeting genetic weakness in some tumors, comments Virginia Tech expert
Virginia Tech

In an invited commentary, Kathleen Mulvaney, assistant professor with the Fralin Biomedical Research Institute at VTC, talks about the potential of a new drug that has shown early promise in clinical trials for solid tumors by killing cancer cells that lack specific tumor suppressor genes.

Released: 31-Oct-2023 1:05 PM EDT
First classification of four stages of heart attack based on heart muscle damage is released
Elsevier

Canadian Cardiovascular Society consensus statement published in the Canadian Journal of Cardiology paves the way for refining treatment and providing individualized care

Newswise: Researchers Show SARS-Cov-2 Infection Affects Energy Stores in the Body, Causing Organ Failure
Released: 31-Oct-2023 11:05 AM EDT
Researchers Show SARS-Cov-2 Infection Affects Energy Stores in the Body, Causing Organ Failure
University of North Carolina School of Medicine

An international research team, including Jonathan C. Schisler, PhD, in the UNC School of Medicine, has found how SARS-CoV-2 causes widespread “energy outages” throughout major organs, and how these effects contribute to debilitating long COVID symptoms.

Newswise: Binghamton researchers get FDA approval for drug to treat world's most common neuromuscular genetic disease
Released: 31-Oct-2023 10:05 AM EDT
Binghamton researchers get FDA approval for drug to treat world's most common neuromuscular genetic disease
Binghamton University, State University of New York

A new drug developed by professors from the School of Pharmacy and Pharmaceutical Sciences at Binghamton University, State University of New York has received FDA approval for the treatment of patients with Duchenne muscular dystrophy, a common genetic disease that mostly affects young boys.

Newswise: Joseph Barone, Dean, Ernest Mario School of Pharmacy at Rutgers, Receives Lifetime Achievement Award
Released: 31-Oct-2023 10:05 AM EDT
Joseph Barone, Dean, Ernest Mario School of Pharmacy at Rutgers, Receives Lifetime Achievement Award
Rutgers University-New Brunswick

Joseph A. Barone, Dean of the Rutgers University Ernest Mario School of Pharmacy, has been selected as the 2023 recipient of the New Jersey Pharmacists Association Lifetime Achievement Award

Not for public release

This news release is embargoed until 30-Oct-2023 5:00 PM EDT Released to reporters: 24-Oct-2023 2:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 30-Oct-2023 5:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 30-Oct-2023 2:30 PM EDT
New Study Shows Shortages of Hair Loss Drug in DMV Pharmacies
George Washington University

In August 2022, a New York Times article highlighted an off-label use of a drug that remedies a type of hair loss. The subsequent media attention led to a surge in interest in the drug known as Minoxidil. Researchers at the George Washington University surveyed pharmacies in the Washington, Maryland and Virginia metro area and found shortages in thirty day supplies of the drug.

Newswise: ‘Plug and play’ nanoparticles could make it easier to tackle various biological targets
27-Oct-2023 2:05 PM EDT
‘Plug and play’ nanoparticles could make it easier to tackle various biological targets
University of California San Diego

UC San Diego engineers have developed modular nanoparticles that can be easily customized to target different biological entities such as tumors, viruses or toxins. The surface of the nanoparticles is engineered to host any biological molecules of choice, making it possible to tailor the nanoparticles for a wide array of applications, ranging from targeted drug delivery to neutralizing biological agents.

Released: 30-Oct-2023 9:05 AM EDT
Center Will Support Healthy Pregnancies by Detecting Placenta Problems Sooner
Rutgers University-New Brunswick

Rutgers teams up with four other universities to form a new research center in Piscataway.

Released: 27-Oct-2023 5:05 PM EDT
Study: Metformin can help youth manage weight gain side effect of bipolar medications
University of Cincinnati

A new large-scale study led by researchers at the University of Cincinnati and Northwell Health, New York's largest health care provider, found the drug metformin can help prevent or reduce weight gain in youth taking medication to treat bipolar disorder.

Released: 27-Oct-2023 12:05 PM EDT
Scientists build on artificial intelligence to create next-generation gastric acid treatment
Nagoya University

Nagoya University researchers used AI to design and synthesize a new, highly effective gastric acid inhibitor, demonstrating the potential of AI in pharmaceutical development.

Released: 27-Oct-2023 8:30 AM EDT
FDA Approves Mirikizumab, a Promising Induction and Maintenance Therapy for Ulcerative Colitis
Mount Sinai Health System

Offers new option with improved quality of life for patients with moderate-to-severely active disease.

Newswise: Common chemotherapy drugs don’t work like doctors thought, with big implications for drug discovery
Released: 26-Oct-2023 5:05 PM EDT
Common chemotherapy drugs don’t work like doctors thought, with big implications for drug discovery
University of Wisconsin–Madison

A new study from the University of Wisconsin–Madison suggests that chemotherapy may not be reaching its full potential, in part because researchers and doctors have long misunderstood how some of the most common cancer drugs actually ward off tumors.

Newswise: UTHealth Houston researchers awarded $3.4M NIH grant to study pharmaceutical therapies to treat acute respiratory distress syndrome
Released: 26-Oct-2023 11:05 AM EDT
UTHealth Houston researchers awarded $3.4M NIH grant to study pharmaceutical therapies to treat acute respiratory distress syndrome
University of Texas Health Science Center at Houston

A four-year, $3.4 million grant to investigate molecular mechanisms and therapeutic treatments for acute respiratory distress syndrome (ARDS) has been awarded to UTHealth Houston researchers by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health.

Newswise: Interprofessional Team from Johns Hopkins Nursing, Public Health, Medicine, and Bayview Receives Top Palliative Care Award from the American Hospital Association
Released: 26-Oct-2023 9:00 AM EDT
Interprofessional Team from Johns Hopkins Nursing, Public Health, Medicine, and Bayview Receives Top Palliative Care Award from the American Hospital Association
Johns Hopkins School of Nursing

The Palliative Care Program at Johns Hopkins Bayview Medical Center, consisting of an interprofessional team of clinicians and researchers from Bayview and Johns Hopkins Schools of Nursing, Public Health, and Medicine, received the 2023 Circle of Life Award from the American Hospital Association.

Released: 26-Oct-2023 8:00 AM EDT
An unexpected link between 2 schizophrenia risk proteins
Ohio State University

The discovery of a physical interaction between two proteins in brain cells that can be traced in mice to control of movement, anxiety and memory could one day open the door to development of new schizophrenia treatment strategies, researchers say.

Newswise: Anti-anxiety drug may improve brain cancer survival chances
Released: 25-Oct-2023 5:05 PM EDT
Anti-anxiety drug may improve brain cancer survival chances
Flinders University

A new research study shows that cerebrospinal fluid reduces current treatment efficacy in brain cancer and identifies new therapeutic opportunities.

Released: 25-Oct-2023 5:05 PM EDT
Oregon State researchers uncover mechanism for treating dangerous liver condition
Oregon State University

A study spearheaded by Oregon State University has shown why certain polyunsaturated fatty acids work to combat a dangerous liver condition, opening a new avenue of drug research for a disease that currently has no FDA-approved medications.

Released: 25-Oct-2023 12:05 PM EDT
Researchers induce brain activation using infrared light-controlled drugs
Institute For Bioengineering Of Catalonia (IBEC)

This cutting-edge technique activates a specific neurotransmitter receptor using mid-infrared light, which can penetrate deep into tissue and offers unparalleled pharmacological and spatiotemporal precision in three dimensions.

Released: 25-Oct-2023 11:05 AM EDT
Global platform study presents results to guide care of severely ill patients with COVID-19 using routinely available drugs
University of Pittsburgh

The world’s largest trial of multiple interventions for critically ill adults with COVID-19 has simultaneously released results about two of its treatments, vitamin C and simvastatin

Not for public release

This news release is embargoed until 23-Oct-2023 5:00 PM EDT Released to reporters: 17-Oct-2023 2:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 23-Oct-2023 5:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

18-Oct-2023 10:55 AM EDT
Better use of existing drugs increases cervical cancer survival and reduces recurrence
University College London

A course of treatment with existing drugs prior to chemoradiation led to a 35% reduction in the risk of death or return of cancer, in trial results presented by researchers from UCL and UCLH.

Released: 22-Oct-2023 2:30 AM EDT
Dual-action drug produces positive results in patients with advanced neuroendocrine tumors, trial finds
Dana-Farber Cancer Institute

Cabozantinib, which targets tumor cell growth and tumor blood vessel growth, sharply improved progression-free survival over placebo in patients with extra-pancreatic and pancreatic neuroendocrine tumors

Newswise: Broad-spectrum antiviral candidate targets dengue and SARS-CoV-2
Released: 20-Oct-2023 1:00 AM EDT
Broad-spectrum antiviral candidate targets dengue and SARS-CoV-2
Hokkaido University

A broad-spectrum antiviral drug candidate, 2-thiouridine, that targets positive-strand RNA viruses has been identified and characterized.

Released: 19-Oct-2023 7:05 PM EDT
Ketamine’s effect on depression may hinge on hope
Stanford Medicine

In study after study, the psychoactive drug ketamine has given profound and fast relief to many people suffering from severe depression.

Released: 19-Oct-2023 7:05 PM EDT
Review: Drug for panic disorder less effective than previously believed
Oregon Health & Science University

New research reveals that the nation’s most widely prescribed type of sedative may be less effective than clinicians and scientists have been led to believe, based on publications in medical journals.

17-Oct-2023 12:05 PM EDT
First-of-its kind hormone replacement treatment shows promise in patient trials
University of Bristol

A first-of-its kind hormone replacement therapy that more closely replicates the natural circadian and ultradian rhythms of our hormones has shown to improve symptoms in patients with adrenal conditions. Results from the University of Bristol-led clinical trial are published today [20 October] in the Journal of Internal Medicine.

Released: 19-Oct-2023 2:05 PM EDT
UC Irvine study reveals surge in use of weight loss-linked drugs in California health system
University of California, Irvine

In a first-of-its-kind study, researchers from the University of California, Irvine have discovered an extraordinary surge in the utilization of weight loss-associated GLP-1 receptor agonists, a class of medications commonly used in the treatment of Type 2 diabetes and obesity, that is poised to accelerate, based on emerging clinical evidence.

Released: 19-Oct-2023 1:05 PM EDT
Medicine on the base of vitamin B6 improves memory and decreases fatigue after COVID
Scientific Project Lomonosov

Scientists have showed that medicine on the base of vitamin B6 can be used for treatment of post-COVID asthenia – condition when patients complain of rapid fatigability, problems with memory and sleep. Taking of this product enabled 35% patients to improve memory, 40% patients began to sleep well, 42% of people began to get tired more slowly. Besides this taking this medicine enabled patients to experience physical activity easier. Results of the research are published in Magazine of Infectology.

16-Oct-2023 6:05 AM EDT
New ‘Subway Map’ of Lyme Disease Pathways Identifies Potential New Treatment Targets
Tufts University

Scientists at Tufts University School of Medicine have developed a genome-scale metabolic model or “subway map” of key metabolic activities of the bacterium that causes Lyme disease.

   


close
2.15344